Foundayo (orforglipron) is the newest option on the weight loss shelf, and the one people ask us about most. It is a once-daily tablet that acts on the same appetite pathway as the injections — but unlike oral semaglutide, it does not have to be taken on an empty stomach, and unlike the pens, it does not need refrigerating.
Orforglipron is a small-molecule GLP-1 receptor agonist. That chemistry is the whole point: because the molecule is small and stable, it survives the gut without an absorption enhancer, so it can be taken with or without food, at any time of day that suits you. No pen, no needles, no fridge, no 30-minute morning window — just a tablet, once a day.
The mechanism is familiar, so the experience is too: appetite falls, portions shrink naturally, and food noise quietens. Dosing starts low and steps up gradually, as with every treatment in this class, because that is what keeps early nausea and constipation tolerable. Weight loss is steady over months rather than sudden, and it works alongside diet and activity changes rather than instead of them.
Foundayo tends to appeal to people who ruled out weight loss treatment because of needles, people who found the empty-stomach rules of oral semaglutide unworkable, and anyone whose day is too unpredictable for a fixed morning routine. Because it is newer, its long-term real-world track record is shorter than semaglutide's — something we will be straight with you about at your consultation rather than glossing over.
Availability of any new treatment moves quickly, so the honest answer on supply and price is the one your pharmacist gives you on the day. Start with the suitability check on our weight loss clinic page — it works out your BMI and books a free consultation, where we go through every option including the injectables and tell you which we would actually recommend for you.
Pharmacist-led weight loss clinic · 1 Lyng Lane, West Bromwich B70 7RW · 0121 500 5756
Start with a free consultation →